Piramal Pharma Sustainability Report 2025‑26 Overview

Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) released its Sustainability Report for FY 2025‑26, emphasizing progress across environmental, social and governance (ESG) pillars under the theme “Advancing Innovation, Leveraging Sustainability.”

Climate and Responsible Operations

  • The company recorded a 22.6% reduction in Scope 1 and Scope 2 greenhouse‑gas emissions compared with the FY 2022 baseline, the lowest‑ever levels in its SBTi‑approved decarbonisation journey.
  • Renewable energy now accounts for 41% of total energy consumption across all operations.
  • Water stewardship saw 2.63 lakh kilolitres of freshwater recycled and reused.
  • Waste management improved with 65% of total waste diverted for recycling.
  • Progress continues against the Science Based Targets initiative (SBTi) roadmap.

Quality and Operational Excellence

  • 38 regulatory inspections were completed, including three USFDA inspections that resulted in zero Official Action Indicated (OAI) observations.
  • The firm conducted 209 customer audits, reinforcing quality and compliance across its global manufacturing network.
  • Digital transformation advanced through the rollout of Catalyst NxGen, implementation of SAP S/4HANA, and expansion of digital quality systems.
  • A US$90 million investment was announced to expand advanced therapeutics capabilities at the Lexington and Riverview facilities.

Governance and People

  • The reporting period recorded zero data‑breach incidents and zero corruption cases.
  • 100% of employees completed ESG training and 100% completed Code of Conduct training.
  • Women represent 30% of the Board and 20.1% of the global workforce.
  • 38% of critical suppliers were assessed against sustainability criteria as part of the responsible supply‑chain programme.

Community Impact

  • Piramal Pharma invested ₹8.98 crore in CSR initiatives, positively impacting nearly 1.8 million people across 112 Aspirational Districts through healthcare and education programmes.

Leadership Commentary

Chairperson Nandini Piramal stated that sustainability is a catalyst for innovation, resilience and long‑term growth, highlighting the company’s commitment to cleaner operations, digital capability enhancement, people development and deeper value‑chain partnerships.

Strategic Framework and Reporting Standards

  • The sustainability agenda is governed by the Sustainability and Risk Management Committee and is built around four pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity, with more than 50 time‑bound targets across 17 material topics.
  • The report follows GRI standards and aligns with SASB and UNGC frameworks.

Corporate Structure

Piramal Pharma operates 17 global development and manufacturing facilities and a distribution network in over 100 countries. Its businesses include Piramal Pharma Solutions (contract development and manufacturing), Piramal Critical Care (hospital generics), and Piramal Consumer Healthcare (OTC and wellness products). An associate, Abbvie Therapeutics India Private Limited, a joint venture with AbbVie, is a market leader in ophthalmology in India.